What is Insmed's astrazeneca milestone — additions?

Insmed (INSM) reported astrazeneca milestone — additions of $0 in Q1 2026.

What does astrazeneca milestone — additions mean?

This represents the gross increase in the value of intangible assets resulting from the achievement of specific clinical, regulatory, or commercial milestones under the AstraZeneca collaboration agreement. These additions reflect the recognition of new intellectual property rights or license expansions as they are earned. Tracking these additions helps investors understand the pace of investment and the successful progression of partnered clinical programs.

Insmed INSM AstraZeneca milestone — Additions

Similar metrics at other companies

ARDXAccrued payments due to AstraZeneca

$0-100%

AVTXAVTX-009 — Collaborative agreement, milestone payment

$12.75M—

SDGROncology, Neurology, and Immunology Product — Total milestones to be received from initial programs

$482M—

NVAXAdjuvant Products Thereafter — Development, tech transfer, launch, and sales milestone payments

$210M—

AVTXAVTX-406 License Assignment — Revenue recognized from milestones to date

$0—

UTHRAdcirca — Milestone payment to be made

$81.25K0.0%

Other financials

Income statement

See full

Revenue$306.0M+230%

Gross profit$258.5M+261%

Operating income-$153.3M+38.2%

Net income-$163.6M+36.3%

EPS (diluted)-$0.76+46.5%

Balance sheet

See full

Cash & equivalents$582.2M+44.4%

Total debt$580.3M-49.2%

Total equity$704.9M+611%

Total assets$2.1B+15.2%

Cash flow

See full

Operating cash flow-$222.7M+15.0%

CapEx$3.5M-65.4%

Free cash flow-$226.2M+16.9%

Valuation

See full

Market cap$23.18B+19.9%

Enterprise value$23.17B+24.5%

P/S28.3×-20.3×

Profitability

See full

Gross margin81.8%+5.3pp

Operating margin-140.6%-43.9pp

Net margin-144.4%-45.3pp

FCF margin-112.5%-35.3pp

Returns & leverage

See full

Return on equity-294.5%—

Debt / equity0.8×-10.7×

Current ratio4.5×-1.4×

Where this comes from

Reported directly by Insmed in its filing.

Tagged under the XBRL concept us-gaap:FinitelivedIntangibleAssetsAcquired1.

The official record: Insmed’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insmed's astrazeneca milestone — additions.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Insmed's astrazeneca milestone — additions?: Insmed (INSM) reported astrazeneca milestone — additions of $0 in Q1 2026.
What does astrazeneca milestone — additions mean?: This represents the gross increase in the value of intangible assets resulting from the achievement of specific clinical, regulatory, or commercial milestones under the AstraZeneca collaboration agreement. These additions reflect the recognition of new intellectual property rights or license expansions as they are earned. Tracking these additions helps investors understand the pace of investment and the successful progression of partnered clinical programs.